CompletedNCT04587791
CBD doses for pain and opioid cravings
About this title
Cannabidiol in Opioid Use Disorder and Chronic Pain
Read the official source — NCT04587791Medication studyAges 18–70United StatesAddiction
Understand this study
Who was this study for?
Listed age limits: 18 years to 70 years.
- Listed locations
- West HavenSee all locations and recruitment
- Study phase
- Early phase 1An early first-in-human or very early safety study, usually focused on how a treatment behaves in the body.
Study information
Study start dateStarted: December 8, 2021
- Recruitment status
- Completed
- Enrollment listed in the registry
- 23
- Sponsor
- Yale University
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Early Phase 1An early first-in-human or very early safety study, usually focused on how a treatment behaves in the body.
- Locations
- United States
- Age range
- From 18 Years to 70 Years
- Official registry ID
- NCT04587791
- Official title
Show the full official title
Cannabidiol Pharmacotherapy for Co-occurring Opioid Use Disorder and Chronic Pain
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
West Haven
Questions about this study
Who is behind this study?
The study sponsor is Yale University, a university.
Did this study involve medication?
Yes. The study involved medication, including 400 mg Cannabidiol, 800 mg Cannabidiol, 1200 mg Cannabidiol and Beta carotene oral solution without CBD.
Who was this study for?
Listed age limits: 18 years to 70 years.
